Chimiothérapie Antiparasitaire, UMR CNRS 8076, BioCIS, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France.
Chimiothérapie Antiparasitaire, UMR CNRS 8076, BioCIS, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France.
Int J Parasitol Drugs Drug Resist. 2017 Dec;7(3):328-336. doi: 10.1016/j.ijpddr.2017.09.002. Epub 2017 Sep 8.
The free-living amoeba (FLA) Acanthamoeba sp. is an opportunistic pathogen that can cause amoebic keratitis (AK) or granulomatous amoebic encephalitis (GAE). While current treatments of AK are long with some relapses, no consensus therapy has been developed for GAE remaining lethal in 90% of the cases. In this context, efficient antiacanthamoebal drugs have to be identified. In this work, 15 drugs used in the treatment of AK or GAE or in other parasitic diseases were evaluated for their in vitro activity on A. castellanii. Hexamidine, voriconazole and clotrimazole exhibited the highest activities with IC values at 0.05 μM, 0.40 μM and 0.80 μM, respectively, while rifampicin, metronidazole and cotrimoxazole were inactive. Among 15 drug associations evaluated, no synergistic effect was observed, and one antagonism was determined between hexamidine and chlorhexidine. Interestingly, amphotericin B was the only drug presenting an increase of IC as a function of treatment duration. The amoebae susceptibility to amphotericin B cultured in the presence of 250 μM of the drug was similar to the one of a naive control, revealing that no resistant strain could be selected. However, the amoebae susceptibility always returned to an initial level at each passage. This natural and non-acquired adaptation to amphotericin B, qualified as resilience, was observed in several strains of A. castellanii and A. polyphaga. Using a pharmacological approach with effectors of different cellular mechanisms or transports, and an ultrastructural analysis of amphotericin B-treated amoebae, the involvement of several mitochondria-dependent pathways as well as multidrug resistant transporters was determined in amphotericin B resilience. Based on the observations from this study, the relevance of using amphotericin B in GAE treatments may be reconsidered, while the use of some other drugs, such as rifampicin or cotrimoxazole, is not relative to intrinsic antiacanthamoebal activity.
自由生活的阿米巴(FLA)棘阿米巴属是一种机会性病原体,可引起阿米巴角膜炎(AK)或肉芽肿性阿米巴脑炎(GAE)。虽然 AK 的当前治疗时间较长,且有些会复发,但对于 90%的致死性 GAE 病例,仍未达成共识的治疗方法。在这种情况下,必须确定有效的抗棘阿米巴药物。在这项工作中,评估了 15 种用于治疗 AK 或 GAE 或其他寄生虫病的药物对棘阿米巴属的体外活性。己脒定、伏立康唑和克霉唑的活性最高,IC 值分别为 0.05 μM、0.40 μM 和 0.80 μM,而利福平、甲硝唑和复方磺胺甲噁唑则无活性。在所评估的 15 种药物联合中,未观察到协同作用,并且己脒定和洗必泰之间存在拮抗作用。有趣的是,两性霉素 B 是唯一一种随着治疗时间的延长而增加 IC 值的药物。在存在 250 μM 药物的情况下培养的棘阿米巴对两性霉素 B 的敏感性与对照敏感的棘阿米巴相似,表明不能选择耐药株。然而,每次传代时,棘阿米巴的敏感性总是恢复到初始水平。这种对两性霉素 B 的自然和非获得性适应,被称为弹性,在几种棘阿米巴属和棘阿米巴属中观察到。使用不同细胞机制或转运的效应物的药理学方法以及对两性霉素 B 处理的阿米巴的超微结构分析,确定了两性霉素 B 弹性涉及几种依赖线粒体的途径以及多药耐药转运蛋白。基于本研究的观察结果,可能需要重新考虑两性霉素 B 在 GAE 治疗中的应用,而使用某些其他药物,如利福平或复方磺胺甲噁唑,则与内在的抗棘阿米巴活性无关。